Advances in imaging to assess response in pancreatic cancer AIR-PANC
Research type
Research Study
Full title
Advances in imaging to assess response in pancreatic cancer (AIR-PANC): A single centre feasibility study
IRAS ID
313810
Contact name
Aileen Duffton
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 6 months, 8 days
Research summary
Currently, we do not routinely assess response during radiotherapy treatment for pancreatic cancer and so patients will have a standard treatment delivered, based on their initial planning scan. Patients are then imaged at follow up with this imaging being used to assess treatment response and decide on further treatment options. More information i.e. more frequent or detailed imaging, captured during and after treatment could help to improve this decision making. In this study magnetic resonance (MR) images will be repeated at intervals during treatment; and a follow up MR scan will be planned for around 4 weeks after treatment. This will allow us to evaluate if repeat scanning is feasible in this patient group. We will also quantify and compare measurements at different treatment timepoints to investigate what they tell us about how the tumour is responding to radiotherapy.
REC name
West of Scotland REC 5
REC reference
22/WS/0070
Date of REC Opinion
22 Jun 2022
REC opinion
Further Information Favourable Opinion